Published October 2017 | Version v1
Journal article Metadata-only

The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapy

Creators

  • 1. Department of Oncology, Velindre Cancer Centre, Cardiff (United Kingdom)
  • 2. Wales Cancer Trials Unit, Cardiff University, Cardiff (United Kingdom)
  • 3. Oncology Institute, Shaare Zedek Medical Centre, Jerusalem (Israel)
  • 4. Department of Oncology, Oxford Cancer Centre, University of Oxford, Churchill Hospital, Oxford (United Kingdom)
  • 5. University College Hospital Macmillan Cancer Centre, London (United Kingdom)

Description

Background and purposeThe derived neutrophil–lymphocyte ratio (dNLR) is a validated prognostic biomarker for cancer survival but has not been extensively studied in locally-advanced oesophageal cancer treated with definitive chemoradiotherapy (dCRT). We aimed to identify the prognostic value of dNLR in patients recruited to the SCOPE1 trial.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.radonc.2017.08.023

Additional details

Identifiers

DOI
10.1016/j.radonc.2017.08.023;
PII
S016781401732546X;

Publishing Information

Journal Title
Radiotherapy and Oncology
Journal Volume
125
Journal Issue
1
Journal Page Range
p. 154-159
ISSN
0167-8140
CODEN
RAONDT

INIS

Country of Publication
Ireland
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
51004952
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
BIOLOGICAL MARKERS; COMBINED THERAPY; LYMPHOCYTES; NEOPLASMS; NEUTROPHILS; PATIENTS
Descriptors DEC
ANIMAL CELLS; BIOLOGICAL MATERIALS; BLOOD; BLOOD CELLS; BODY FLUIDS; CONNECTIVE TISSUE CELLS; DISEASES; LEUKOCYTES; MATERIALS; MEDICINE; SOMATIC CELLS; THERAPY

Optional Information

Copyright
Copyright (c) 2017 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.